Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach

Monika Fischer, Brian Sipe, Yao Wen Cheng, Emmalee Phelps, Nicholas Rogers, Sashidhar Sagi, Matthew Bohm, Huiping Xu, Zain Kassam

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Severe and severe-complicated Clostridium difficile infection (CDI) is associated with high morbidity and mortality. Colectomy is standard of care; however, post-surgical mortality rates approach 50%. Case reports suggest fecal microbiota transplant (FMT) is a promising treatment of severe and severe-complicated disease but there is a paucity of data. Here, we present a single center experience with a novel sequential FMT protocol for patients refractory to maximal medical therapy. This approach consists of at least one FMT delivered via colonoscopy with criteria for repeat FMT and continued vancomycin therapy based on clinical response and pseudomembranes. Our cohort included 57 consecutive inpatients diagnosed with severe or severe-complicated CDI and treated with FMT. Overall, 91% (52/57) experienced clinical cure at 1 month with a 100% cure rate among severe CDI (n = 19) patients and an 87% cure rate for severe-complicated CDI (n = 33) patients. For the cohort, the survival rate was 94.7% at 1 month and 78.6% at 3 months. There were no serious adverse events related to FMT including no procedure-related complications or perforation. There was no difference in outcome between fresh or frozen fecal material. Sequential FMT for inpatients with severe or severe-complicated CDI is promising and may be preferred over colectomy in certain patients.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalGut Microbes
DOIs
StateAccepted/In press - Jan 13 2017

Fingerprint

Clostridium difficile
Microbiota
Clostridium Infections
Colectomy
Therapeutics
Inpatients
Mortality
Colonoscopy
Vancomycin
Standard of Care
Fecal Microbiota Transplantation
Survival Rate
Morbidity

Keywords

  • Fecal microbiota transplant
  • FMT
  • fulminant C. difficile
  • pseudomembranes
  • severe and complicated C. difficile infection
  • severe C. difficile infection

ASJC Scopus subject areas

  • Microbiology
  • Gastroenterology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Fecal microbiota transplant in severe and severe-complicated Clostridium difficile : A promising treatment approach. / Fischer, Monika; Sipe, Brian; Cheng, Yao Wen; Phelps, Emmalee; Rogers, Nicholas; Sagi, Sashidhar; Bohm, Matthew; Xu, Huiping; Kassam, Zain.

In: Gut Microbes, 13.01.2017, p. 1-14.

Research output: Contribution to journalArticle

@article{237fb2e81c494fe78b41de2c08c16974,
title = "Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach",
abstract = "Severe and severe-complicated Clostridium difficile infection (CDI) is associated with high morbidity and mortality. Colectomy is standard of care; however, post-surgical mortality rates approach 50{\%}. Case reports suggest fecal microbiota transplant (FMT) is a promising treatment of severe and severe-complicated disease but there is a paucity of data. Here, we present a single center experience with a novel sequential FMT protocol for patients refractory to maximal medical therapy. This approach consists of at least one FMT delivered via colonoscopy with criteria for repeat FMT and continued vancomycin therapy based on clinical response and pseudomembranes. Our cohort included 57 consecutive inpatients diagnosed with severe or severe-complicated CDI and treated with FMT. Overall, 91{\%} (52/57) experienced clinical cure at 1 month with a 100{\%} cure rate among severe CDI (n = 19) patients and an 87{\%} cure rate for severe-complicated CDI (n = 33) patients. For the cohort, the survival rate was 94.7{\%} at 1 month and 78.6{\%} at 3 months. There were no serious adverse events related to FMT including no procedure-related complications or perforation. There was no difference in outcome between fresh or frozen fecal material. Sequential FMT for inpatients with severe or severe-complicated CDI is promising and may be preferred over colectomy in certain patients.",
keywords = "Fecal microbiota transplant, FMT, fulminant C. difficile, pseudomembranes, severe and complicated C. difficile infection, severe C. difficile infection",
author = "Monika Fischer and Brian Sipe and Cheng, {Yao Wen} and Emmalee Phelps and Nicholas Rogers and Sashidhar Sagi and Matthew Bohm and Huiping Xu and Zain Kassam",
year = "2017",
month = "1",
day = "13",
doi = "10.1080/19490976.2016.1273998",
language = "English (US)",
pages = "1--14",
journal = "Gut Microbes",
issn = "1949-0976",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Fecal microbiota transplant in severe and severe-complicated Clostridium difficile

T2 - A promising treatment approach

AU - Fischer, Monika

AU - Sipe, Brian

AU - Cheng, Yao Wen

AU - Phelps, Emmalee

AU - Rogers, Nicholas

AU - Sagi, Sashidhar

AU - Bohm, Matthew

AU - Xu, Huiping

AU - Kassam, Zain

PY - 2017/1/13

Y1 - 2017/1/13

N2 - Severe and severe-complicated Clostridium difficile infection (CDI) is associated with high morbidity and mortality. Colectomy is standard of care; however, post-surgical mortality rates approach 50%. Case reports suggest fecal microbiota transplant (FMT) is a promising treatment of severe and severe-complicated disease but there is a paucity of data. Here, we present a single center experience with a novel sequential FMT protocol for patients refractory to maximal medical therapy. This approach consists of at least one FMT delivered via colonoscopy with criteria for repeat FMT and continued vancomycin therapy based on clinical response and pseudomembranes. Our cohort included 57 consecutive inpatients diagnosed with severe or severe-complicated CDI and treated with FMT. Overall, 91% (52/57) experienced clinical cure at 1 month with a 100% cure rate among severe CDI (n = 19) patients and an 87% cure rate for severe-complicated CDI (n = 33) patients. For the cohort, the survival rate was 94.7% at 1 month and 78.6% at 3 months. There were no serious adverse events related to FMT including no procedure-related complications or perforation. There was no difference in outcome between fresh or frozen fecal material. Sequential FMT for inpatients with severe or severe-complicated CDI is promising and may be preferred over colectomy in certain patients.

AB - Severe and severe-complicated Clostridium difficile infection (CDI) is associated with high morbidity and mortality. Colectomy is standard of care; however, post-surgical mortality rates approach 50%. Case reports suggest fecal microbiota transplant (FMT) is a promising treatment of severe and severe-complicated disease but there is a paucity of data. Here, we present a single center experience with a novel sequential FMT protocol for patients refractory to maximal medical therapy. This approach consists of at least one FMT delivered via colonoscopy with criteria for repeat FMT and continued vancomycin therapy based on clinical response and pseudomembranes. Our cohort included 57 consecutive inpatients diagnosed with severe or severe-complicated CDI and treated with FMT. Overall, 91% (52/57) experienced clinical cure at 1 month with a 100% cure rate among severe CDI (n = 19) patients and an 87% cure rate for severe-complicated CDI (n = 33) patients. For the cohort, the survival rate was 94.7% at 1 month and 78.6% at 3 months. There were no serious adverse events related to FMT including no procedure-related complications or perforation. There was no difference in outcome between fresh or frozen fecal material. Sequential FMT for inpatients with severe or severe-complicated CDI is promising and may be preferred over colectomy in certain patients.

KW - Fecal microbiota transplant

KW - FMT

KW - fulminant C. difficile

KW - pseudomembranes

KW - severe and complicated C. difficile infection

KW - severe C. difficile infection

UR - http://www.scopus.com/inward/record.url?scp=85009821218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009821218&partnerID=8YFLogxK

U2 - 10.1080/19490976.2016.1273998

DO - 10.1080/19490976.2016.1273998

M3 - Article

C2 - 28001467

AN - SCOPUS:85009821218

SP - 1

EP - 14

JO - Gut Microbes

JF - Gut Microbes

SN - 1949-0976

ER -